ABUS - Arbutus Biopharma Corp - Stock Forecast

Healthcare - Sector
Coverage Performance Price Targets & Ratings Chart Insider Trading

ABUS is currently covered by 3 analysts with an average price target of $5.3. This is a potential upside of $2.38 (81.51%) from yesterday's end of day stock price of $2.92.

Arbutus Biopharma Corp's activity chart (see below) currently has 36 price targets and 45 ratings on display. The stock rating distribution of ABUS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 30.99% with an average time for these price targets to be met of 38.33 days.

Highest price target for ABUS is $3, Lowest price target is $2, average price target is $5.3.

Most recent stock forecast was given by ED ARCE from HC WAINWRIGHT on 12-Sep-2023. First documented stock forecast 16-Jun-2016.

Currently out of the existing stock ratings of ABUS, 15 are a BUY (100%).

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score


5 months 16 days ago

0/3 (0%)

$3.1 (106.90%)


6 months 24 days ago

1/5 (20%)

$3.14 (109.79%)




7 months 22 days ago

0/1 (0%)

$2.9 (93.55%)



$2.08 (71.23%)

2 years 26 days ago

0/1 (0%)

$2.11 (73.01%)



2 years 8 months ago

0/2 (0%)

$3.7 (112.12%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ABUS (Arbutus Biopharma Corp) average time for price targets to be met?

On average it took 38.33 days on average for the stock forecasts to be realized with a an average price target met ratio 30.99

Which analyst has the current highest performing score on ABUS (Arbutus Biopharma Corp) with a proven track record?


Which analyst has the current lower performing score on ABUS (Arbutus Biopharma Corp) with a proven track record?


Which analyst has the most public recommendations on ABUS (Arbutus Biopharma Corp)?

Gbola Amusa works at CHARDAN CAPITAL and has 5 price targets and 4 ratings on ABUS

Which analyst is the currently most bullish on ABUS (Arbutus Biopharma Corp)?

Mayank Mamtani with highest potential upside - $4.08

Which analyst is the currently most reserved on ABUS (Arbutus Biopharma Corp)?

Keay Nakae with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?